Taro Pharmaceutical Industries Ltd. Ordinary Shares (TARO): Price and Financial Metrics


Taro Pharmaceutical Industries Ltd. Ordinary Shares (TARO): $62.78

-0.39 (-0.62%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TARO POWR Grades


  • Value is the dimension where TARO ranks best; there it ranks ahead of 95.29% of US stocks.
  • TARO's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
  • TARO ranks lowest in Momentum; there it ranks in the 5th percentile.

TARO Stock Summary

  • The price/operating cash flow metric for Taro Pharmaceutical Industries Ltd is higher than 95.19% of stocks in our set with a positive cash flow.
  • For TARO, its debt to operating expenses ratio is greater than that reported by just 0.49% of US equities we're observing.
  • The volatility of Taro Pharmaceutical Industries Ltd's share price is greater than that of only 4.05% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Taro Pharmaceutical Industries Ltd are MTP, CMTL, LIVN, HSTM, and SSRM.
  • TARO's SEC filings can be seen here. And to visit Taro Pharmaceutical Industries Ltd's official web site, go to www.taro.com.

TARO Valuation Summary

  • In comparison to the median Healthcare stock, TARO's price/sales ratio is 15.79% higher, now standing at 4.4.
  • TARO's price/earnings ratio has moved up 82 over the prior 243 months.
  • Over the past 243 months, TARO's price/sales ratio has gone up 2.2.

Below are key valuation metrics over time for TARO.

Stock Date P/S P/B P/E EV/EBIT
TARO 2021-08-31 4.4 1.6 87.2 148.4
TARO 2021-08-30 4.4 1.5 86.7 147.2
TARO 2021-08-27 4.5 1.6 87.5 149.1
TARO 2021-08-26 4.5 1.6 89.1 152.7
TARO 2021-08-25 4.6 1.6 90.2 155.2
TARO 2021-08-24 4.5 1.6 88.9 152.2

TARO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TARO has a Quality Grade of B, ranking ahead of 79.92% of graded US stocks.
  • TARO's asset turnover comes in at 0.243 -- ranking 182nd of 677 Pharmaceutical Products stocks.
  • PLXP, DRNA, and CASI are the stocks whose asset turnover ratios are most correlated with TARO.

The table below shows TARO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.243 0.535 0.011
2021-03-31 0.231 0.540 -0.326
2021-03-31 0.231 0.540 -0.310
2020-12-31 0.244 0.559 -0.238
2020-09-30 0.249 0.588 -0.202
2020-06-30 0.260 0.604 -0.179

TARO Stock Price Chart Interactive Chart >

Price chart for TARO

TARO Price/Volume Stats

Current price $62.78 52-week high $80.00
Prev. close $63.17 52-week low $53.95
Day low $61.97 Volume 1,932
Day high $63.31 Avg. volume 24,206
50-day MA $68.88 Dividend yield N/A
200-day MA $72.75 Market Cap 2.38B

Taro Pharmaceutical Industries Ltd. Ordinary Shares (TARO) Company Bio


Taro Pharmaceutical Industries offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company was founded in 1959 and is based in Haifa Bay, Israel.


TARO Latest News Stream


Event/Time News Detail
Loading, please wait...

TARO Latest Social Stream


Loading social stream, please wait...

View Full TARO Social Stream

Latest TARO News From Around the Web

Below are the latest news stories about Taro Pharmaceutical Industries Ltd that investors may wish to consider to help them evaluate TARO as an investment opportunity.

Onychomycosis Treatment Market revenue to cross USD 6.2 Bn by 2027: Global Market Insights Inc.

Major onychomycosis treatment market players include Pfizer Inc., Novartis AG, Bausch Health Sciences, Dr. Reddys Laboratories, Galderma Laboratories, Merz Pharma, Moberg Pharma AB, Medimetriks Pharmaceuticals, Johnson and Johnson Services Inc., Taro Pharmaceuticals and GSK Plc. Major onychomycosis treatment market players include Pfizer Inc., Novartis AG, Bausch Health Sciences, Dr. Reddys Laboratories, Galderma Laboratories, Merz Pharma, Moberg Pharma AB, Medimetriks Pharmaceuticals, Johnson and Johnson Services Inc., Taro Pharmaceuticals and GSK Plc.

Intrado Digital Media | August 16, 2021

Global Hydrocortisone Butyrate Market Research Report 2021 | Merck,Taro Pharmaceutical Industries

Global Info Research offers an overarching research and analysis-based study on, Global Hydrocortisone Butyrate Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026. The Hydrocortisone Butyrate market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, []

Jumbo News | August 3, 2021

Does The Market Have A Low Tolerance For Taro Pharmaceutical Industries Ltd.'s (NYSE:TARO) Mixed Fundamentals?

It is hard to get excited after looking at Taro Pharmaceutical Industries' (NYSE:TARO) recent performance, when its...

Yahoo | July 29, 2021

Taro Pharmaceutical (TARO) Q1 Earnings and Revenues Beat Estimates

Taro (TARO) delivered earnings and revenue surprises of 29.76% and 7.23%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | July 28, 2021

Taro Pharmaceutical (TARO) Q1 Earnings and Revenues Beat Estimates | Investing.com

Stocks Analysis by Zacks Investment Research covering: Taro Pharmaceutical Industries Ltd. Read Zacks Investment Research''s latest article on Investing.com

Investing.com | July 27, 2021

Read More 'TARO' Stories Here

TARO Price Returns

1-mo -7.77%
3-mo -12.76%
6-mo -15.83%
1-year 15.38%
3-year -36.13%
5-year -44.63%
YTD -14.49%
2020 -16.50%
2019 3.89%
2018 -19.17%
2017 -0.53%
2016 -31.89%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9024 seconds.